Alimera Sciences to Present at Two Investor Conferences in September
Press Release Source: Alimera Sciences, Inc. On Wednesday September 8, 2010, 5:00 pm EDT
ATLANTA, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM - News), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer, will present at the following investor conferences:
The Rodman & Renshaw Annual Global Investment Conference to be held September 12-15, 2010 at the New York Palace Hotel in New York City. The presentation is scheduled for September 14, 2010 at 4:55 p.m. ET.
The Stifel Nicolaus Healthcare Conference 2010 to be held September 15-17, 2010 at the Four Seasons Hotel in Boston. The presentation is scheduled for September 15, 2010 at 3:50 p.m. ET.
Both presentations will be webcast live and can be accessed at www.alimerasciences.com. For those who are not available to listen to the live broadcasts, the presentations will be archived for 30 days.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, Iluvien(R), is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien(R) is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
finance.yahoo.com |
